Dr Pallavi Prasad, MD, DNB ( Nephrology)
@drpallaviprasad.bsky.social
📤 530
📥 107
📝 177
Nephrologist 🩺 Associate Professor 📚 Bookworm 🐛 Amateur gardener 🪴Travel enthusiast 🧳
Hi everyone! Pallavi from New Delhi. No COI
#NephJC
Using flozins occasionally in transplants-mostly in those with proteinuria+-PTDM.
21 days ago
1
6
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
26 days ago
moving on from IgAN to FSGS: BI 764198 a TRPC6 inhibitor reduces proteinuria in an N = 67 phase 2 RCT
www.thelancet.com/journals/lan...
in
@thelancet.com
#NephSky
loading . . .
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02255-X/abstract?rss=yes
2
12
6
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
ASN Publications
about 1 month ago
Editors’ Choice 2025: Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial This phase 2 trial tested ravulizumab, a complement C5 inhibitor, in adults with IgA nephropathy. Check out the paper here:
kidney.pub/JASN0534
0
2
3
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
about 1 month ago
Sodium-Glucose Cotransporter-2 Inhibitors #SGLT2i and #Cardiorenal Events in #Nonalbuminuric Kidney Disease #VisualAbstract by
Augusto Cesar S Santos Jr
https://www.kireports.org/article/S2468-0249(25)00774-0/fulltext
#SGLT2i
#Cardiorenal
#Nonalbuminuric
#VisualAbstract
whuang0824
0
3
3
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
about 2 months ago
1/10 Last
#NephJC
we discussed Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
#TenPostNephJC
Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit.
www.nejm.org/doi/full/10....
1
8
10
Hi everyone! Pallavi from New Delhi. No COI
#NephJC
about 2 months ago
3
5
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
about 2 months ago
Check out the VA for VALIANT from
@nephromommy-akshu.bsky.social
#NephJC
www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract
loading . . .
VALIANT: The Visual Abstract — NephJC
The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-com...
https://www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract
0
13
10
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
3 months ago
The LIBERATE-D VA by
@sejalplakhani.bsky.social
Should we break the pattern of thrice weekly dialysis in AKI-D?
#NephJC
#NephSky
www.nephjc.com/news/liberateva
loading . . .
LIBERATE-D: The Visual Abstract — NephJC
In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check ou...
https://www.nephjc.com/news/liberateva
0
8
9
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
3 months ago
Join us for the last
#NephJC
of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial
#NephSky
This one might just change your mind 🧠🧠 Blog by
@msocomd.bsky.social
and
@sejalplakhani.bsky.social
www.nephjc.com/news/liberated-aki
loading . . .
Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
https://www.nephjc.com/news/liberated-aki
2
12
13
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
3 months ago
1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC Read the article 👇
www.nejm.org/doi/10....
#NephJC
1
9
9
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
4 months ago
T3f:
#NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA). Do you think either has the advantage?
2
12
7
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
4 months ago
T0k: #NephJC The 96-week extension demonstrated durability: ⬇️proteinuria fell 52% ⬇️Gd-IgA1 dropped 66% ⬇️hematuria declined 75% ⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m² ⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
#NephJC
1
9
5
Hi everyone! Pallavi from New Delhi ! The day light saving change in
#NephJC
doesn't help when in India - approaching time to leave for work..will be lurking . Excited about targeted therapeutic approaches in IgAN . No COI.
4 months ago
0
4
0
Day light saving always confuses me. One hour early for
#NephJC
🥲 and wondering where everyone else is! 😂
4 months ago
0
1
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
4 months ago
Check out the awesome visual abstract by
@salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
loading . . .
ORIGIN-3: The Visual Abstract — NephJC
Atacicept, BAFF/APRIL inhibition in IgAN
https://www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
0
12
14
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
4 months ago
APRIL/BAFF inhibition: 🎯💊🩺 Trials are under way on this pathway, which promise to get to the root cause of IgAN. However, with great innovation comes…greater confusion. Sequence of treatment, cost, and side effects will need to be considered when increasing immunosuppression.
#NephJC
1
5
1
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
4 months ago
BTW super interesting basket trial from India (Ongoing)
bsky.app/profile/hswa...
Maybe they can eventually add a povetacicept arm 😏
#NephJC
add a skeleton here at some point
1
3
2
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
4 months ago
Treatment Approach: 💊 Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach. a) Generic responses to HTN/proteinuria b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD.
#NephJC
5
16
5
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
4 months ago
Let’s recapitulate the history and evidence-based developments of IgA Nephropathy. We’ve known about the pathologic etiology for decades, however there was a huge therapeutic plateau until quite recently. 💉💊 In the last few years, new therapies are coming up rapidly.
#NephJC
2
4
3
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
4 months ago
The 2025
@kdigo.org
IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over
#Nephsky
#Medsky
✍️Summary by
@thekidneywhisperer.bsky.social
and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
loading . . .
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
https://www.nephjc.com/news/igan-kdigo-2025
1
22
16
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
4 months ago
⏩ Next
#NephJC
is on IgA nephropathy
@kdigo.org
guideline 🎨 Nice visual summary by
@roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
loading . . .
KDIGO 2025 IgA guidelines - Visual Abstract — NephJC
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera
https://www.nephjc.com/news/2025/10/27/kdigo-2025-iga-guidelines-visual-abstract
0
20
18
Apart from myeloma and MGRS , what other diseases should we think of in case of increased UPCR with no albumunuria in urine analysis. Urine alb- trace UPCR-5.2 SIFE,SFLC - normal
@askrenal.bsky.social
#askrenal
#Nephsky
4 months ago
2
4
3
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
4 months ago
1/10 Last #NephJC we tried to answer the question whether protein supplementation increases health related QoL 🥩💊#TenPostNephJC . Read the article 👇
pubmed.ncbi.nlm.nih....
#NephJC
1
8
6
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
5 months ago
⏰30 min before the
#NephJC
chat Let's learn about the Gurus who paved the path to make kidney transplant “Mission Impossible to Mission Possible” with their research.
0
8
2
Hello everyone! Pallavi here from New Delhi. No COI.
#NephJC
5 months ago
1
4
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Jordy Cohen
6 months ago
www.nejm.org/doi/full/10....
There’s some trial data on prevention of albuminuria
#nephjc
loading . . .
Preventing Microalbuminuria in Type 2 Diabetes | NEJM
The multicenter double-blind, randomized Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting–enzyme inhibitors and non-dihydropyridine ...
https://www.nejm.org/doi/full/10.1056/NEJMoa042167
2
12
6
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
6 months ago
T2l Initiation of 2 first-line agents is still recommended for Stage 2 HTN but there is a new emphasis on using single-pill combinations. One pill goes down easier than two! What’s your favorite combo pill? Not using combo pills – what’s holding you back? #NephJC
www.thelancet.com/jo...
#NephJC
0
8
2
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
6 months ago
Check out the insightful VA that makes sense of the updates 🧠
#nephjc
VA by
@sejalplakhani.bsky.social
1
8
6
Hi everyone! Pallavi from New Delhi. no COI.
#NephJc
6 months ago
1
3
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
6 months ago
Finally, the concurrent results of the ALCHEMIST trial (
www.sciencedirect.co...
) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients.
#NephJC
Infographic by @nephroseeker.medsky.socia
1
13
8
Hi everyone! Pallavi from New Delhi, joining
#Nephjc
after a long hiatus. lurking today .. No COI.
6 months ago
0
3
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
8 months ago
The
#NephJC
editorial team knows that plenty of papers deserve attention between our bi-monthly, full-length discussions ✨Enter
#NephJCShorts
- quick hits with a critical eye 🦅 on high-impact reads
www.nephjc.com/news/nephjc-...
#MedSky
#NephSky
loading . . .
Introducing NephJC Shorts — NephJC
In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...
https://www.nephjc.com/news/nephjc-shorts
0
11
11
#NephJC
add a skeleton here at some point
8 months ago
0
3
0
Hi everyone! Good morning from Kerala, God's own country. will be lurking today. COI: flozinator >> RAASblocker
8 months ago
2
3
1
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Michelle Rheault, MD
8 months ago
From Rivka Galchen’s article in
@newyorker.com
: “The kidney, a tremendously under-celebrated organ, basically does four-dimensional sudoku with ions.” And that’s how I’m going to explain it from now on.
1
36
10
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Swapnil Hiremath 🍁🇨🇦
9 months ago
Hilarious (and sobering) essay on the use of AI in medical research & manuscript writing Read the whole thing! John Daugirdas has been on the cutting edge of tech in meded before
#MedEd
was thing
onlinelibrary.wiley.com/doi/10.1111/...
#MedSky
#NephSky
loading . . .
Use of Artificial Intelligence in Scientific Writing. The Danger of Trying Too Hard to Please
The author describes his experience using several artificial intelligence programs to assist in the process of editing or preparing manuscripts for publication. While the programs were very useful to...
https://onlinelibrary.wiley.com/doi/10.1111/hdi.13270?af=R
4
19
15
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
10 months ago
1/10 Last
#NephJC
we discussed the role of prophylactic DDAVP for preventing post kidney biopsy (KBx) bleed
#TenPostNephJC
. The articles 👇
@kireports.bsky.social
@asnpublications.bsky.social
@jeyakumarmeyyappan.bsky.social
www.kireports.org/article/S246...
pubmed.ncbi.nlm.nih.gov/40067357/
1
11
8
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Dr Satoshi Akima, FRACP
10 months ago
Again in the haemostasiology world, we do not favour the use of bleeding times. The trend is toward viscoelastic methods and thrombin generation assays. These need to be studied in nephrology too.
#NephJC
1
4
2
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
10 months ago
Don´t forget to advocate the resolution led by Guatemala on #WHA78: 🌍 Chronic kidney disease affects over 850M We must shift from silent neglect to strategic action. Awareness, prevention, and equity in care are our next steps. #NephJC @theisn.org #NephSky #MedSky
www.thelancet.com/jo...
1
10
7
Hi everyone! Pallavi from New Delhi. No COI. Have used desmopressin for high risk patients
#Nephjc
10 months ago
2
5
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Andrew Michael South, MD, MS
10 months ago
Alright
#PedNeph
#NephTwitter
#NephJC What do you think? Truly a comparative effectiveness trial? Tacrolimus or Mycophenolate Mofetil for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial
jamanetwork.com/journals/jam...
loading . . .
Tacrolimus or Mycophenolate Mofetil for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome
This randomized clinical trial conducted at 12 pediatric nephrology centers in China compares the effectiveness and safety of tacrolimus and mycophenolate mofetil in children with frequently relapsing...
https://jamanetwork.com/journals/jamapediatrics/fullarticle/2833569
1
6
4
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
10 months ago
1/10 We were delighted to discuss the first ever @KDIGO ADPKD guidelines this March! So satisfied with the chat itself that we forgot to post the
#TenPostsNephJC
😉 So here we are! Better late than never.#NephJC
kdigo.org/guidelines/a...
1
15
8
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
KDIGO
11 months ago
We are pleased to announce the publication of the KDIGO 2025 Guideline for Nephrotic Syndrome in Children—an update to Chapter 4 of the KDIGO 2021 Glomerular Diseases Guideline. 📄 Read in
@kidneyint.bsky.social
:
kdigo.co/Nephrotic-Sy...
🧵More below ⬇️
1
15
12
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Alex Chang, MD
11 months ago
Nephro-pharmacists like Wendy St Peter are trying very hard to educate across disciplines with their learning collaborative AKHOMM (dont think theyre on bluesky but will let them know!)
www.kidneymedicationmanagement.org
pubmed.ncbi.nlm.nih.gov/39552516/
loading . . .
Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consens...
The NKF Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions suggests that health systems, health settings, clinical laboratories, electronic health record systems, compen...
https://pubmed.ncbi.nlm.nih.gov/39552516/
1
9
6
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
11 months ago
T3c:
#nephjc
🔸7% survival boost with continued metformin in CKD4+ challenges current restrictions 🔸Benefit persists despite observational design, bolstered by rigorous target-trial methods 🔸Aligns with prior data showing glycemic deterioration post-discontinuation
2
7
1
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
11 months ago
T0i:
#NephJC
Evidence supporting strict metformin discontinuation in CKD is limited. MALA risk it’s the "acid-ental perfect storm" made by pH and low eGFR. It often occurs with acute stressors like heart failure, sepsis, shock, or AKI, which can happen at any GFR
4
12
6
Hi everyone! Late to
#NephJC
and lurking today despite being really interested in this topic. Recovering from a bad viral 🤕. No COI.
11 months ago
1
8
0
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
11 months ago
Hey
#NephSky
&
#MedSky
9pm EST 4/15/25, only on
#Bluesky
Discussion on the use of metformin in advanced CKD. Worried about lactic acidosis 💪?! What's the evidence that an eGFR < 30 ml/min is the ideal cutoff ✂️? Are there benefits to continuing 💊
www.nephjc.com/news/metformin-tte
loading . . .
Metformin- Should I Stay or Should I Go — NephJC
This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
https://www.nephjc.com/news/metformin-tte
2
15
11
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Nephrology Journal Club
11 months ago
Hey
#NephSky
and
#MedSky
Check out the VA for our discussion 4/15/25 at 9pm EST Metformin-Should I Stay or Should I Go (in patients with advanced CKD) VA by
@nephroseeker.medsky.social
www.nephjc.com/news/metformin-ckd-va
loading . . .
Metformin in Advanced CKD — NephJC
Should we continue metformin in eGFR under 30 ml/min? The visual abstract by Cristina Popa summarizes the conclusions from the Scottish cohort using target trial methodology.
https://www.nephjc.com/news/metformin-ckd-va
0
13
11
reposted by
Dr Pallavi Prasad, MD, DNB ( Nephrology)
Cristina Popa
11 months ago
The
@ukkidney.org
guidelines are very on point with both MIC and PROPKD when it comes to prognosis—they make clinicians' job easier
#nephjc
www.ukkidney.org/sites/defaul...
1
8
4
Load more
feeds!
log in